IPH Ltd. Earnings Call: Canada Shines, ANZ Struggles

IPH Ltd. ((AU:IPH)) has held its Q2 earnings call. Read on for the main highlights of the call.

IPH Ltd.’s latest earnings call struck a cautiously upbeat tone as management balanced solid group growth with clear regional headwinds and market risks. Revenue, earnings and cash flow all advanced, the dividend was lifted and leverage fell, reinforcing confidence in the business model even as ANZ pressures, tax changes and FX swings took some shine off the numbers.

Group Revenue Growth

IPH reported total revenue of $363.9 million, a 6.5% year‑on‑year rise powered by the Bereskin & Parr acquisition and organic gains in Canada and Asia. Like‑for‑like revenue edged up 0.7%, indicating that most of the headline growth still reflects scale benefits from recent deals rather than broad‑based market strength.

Underlying EBITDA and Profit Improvements

Underlying EBITDA increased 6.6% to $107.1 million, with like‑for‑like EBITDA up 3.2% and margin expanding 0.7 percentage points. Statutory net profit after tax climbed 10.5%, while underlying NPATA rose 2.6% to $62.6 million, showing modest profit leverage despite regional and currency drags.

Strong Cash Generation and Dividend

Cash conversion remained a standout, with gross operating cash flow equal to 101% of EBITDA and free cash flow rising 32% over the period. Supported by that cash strength, the board lifted the interim dividend by 11.8% to $0.19 per share, implying an 81% payout ratio on cash‑adjusted NPAT.

Canada: Major Turnaround and Scale

Canada delivered a major earnings swing, with like‑for‑like revenue up 7.3% and underlying EBITDA up 18.9% as integration of Bereskin & Parr hit its stride. The segment now contributes more than one‑third of group earnings, with an annualized run rate of about $323 million in revenue and EBITDA above $83 million alongside over 10,000 patent filings.

Asia Returning to Growth

Asia moved back into growth mode, posting like‑for‑like revenue up 3.5% and EBITDA up 1.5% as filings excluding Singapore rose 7.3%. Market share gains were particularly striking in Hong Kong, Vietnam, the Philippines and Brunei, and more than 2,200 case transfers into Asia are deepening the region’s pipeline.

Market Leadership and Network Strength

Management emphasised IPH’s position as the number‑one patent group in Australia, Canada, Singapore and New Zealand, and the top filer in Indonesia. A network spanning seven brands and roughly 1,700 employees across about 26 intellectual property jurisdictions underpins cross‑border referrals and diversifies earnings.

Client Referrals and Case Transfers

Cross‑regional collaboration is accelerating, with nearly 1,200 cumulative client referrals between IPH Canada and Asia since 2022, and volumes almost doubling over the past year. Recent wins include around 100 patent case transfers into Southeast Asia, China and Australia, plus about 500 patent transfers into ANZ, supporting future revenue.

Cost Discipline and Corporate Savings

Corporate costs fell by $2.5 million in the half, helping lift the group’s underlying EBITDA margin by 0.1 percentage points despite ANZ softness. Management linked the improvement to FY 2025 cost realignment efforts and ongoing discipline, signaling further room to protect margins as demand fluctuates.

Balance Sheet and Capital Management

Net debt fell 6.5% (around $27 million), taking leverage down to 1.8 times EBITDA and comfortably within the stated ceiling of 2 times. The group refinanced $210 million of syndicated debt on better pricing, retains $111 million of undrawn facilities and has launched an on‑market share buyback of up to 12.2 million shares.

Operational Efficiency and Technology Adoption

Capital expenditure was kept low at $1.5 million versus $6.1 million in the prior period, reflecting a lighter investment cycle. At the same time, IPH is embedding AI and automation into patent drafting, prosecution and administrative workflows to streamline operations and compress unit costs over time.

ANZ Revenue and Earnings Decline

The ANZ business was the weak spot, with like‑for‑like revenue down 6.1% and underlying EBITDA down 10.6% amid a sharp fall in U.S. PCT‑linked work. The broader Australian patent market dropped 12.9%, while IPH’s filings fell 5.4%, or 4.8% after excluding self‑filed applications, highlighting relative resilience but clear profit pressure.

CIPO Backlog and Timing Uncertainty

In Canada, a post‑upgrade backlog at the Canadian Intellectual Property Office continues to delay revenue recognition across the system. Management framed the bottleneck as a future earnings opportunity but admitted there has been no meaningful clearance yet and the timing of a normalization remains uncertain.

Higher Effective Tax Rate Post‑Acquisition

The group’s underlying effective tax rate jumped from 20.4% to 26.2% following Canadian acquisitions and a changed geographic profit mix. Executives signaled that investors should now treat this higher tax rate as the new normal rather than a temporary spike, limiting some of the benefit from earnings growth.

Margin Pressure in ANZ and Employee Costs

Margin compression in ANZ offset gains in other regions and weighed on group profitability. Employee benefits expenses rose 6.8%, largely due to integration of acquired staff, though management said ongoing savings initiatives are helping to blunt the impact of higher people costs.

Singapore Market Weakness and Client Concentration

Singapore remained a soft patch, with the patent filing market down 8.6% year‑to‑date to November and IPH filings falling 13.9%. One major client sharply reduced activity, and even on a normalized basis IPH’s filings were down about 10%, underscoring lingering client concentration risks in some jurisdictions.

Foreign Exchange and Translation Impacts

Currency swings slightly dented reported results, with a $0.2 million net FX loss compared with a $1.3 million gain previously. FX translation also pulled down the foreign currency reserve by $14.1 million and reduced intangible assets by about $19.1 million, modestly compressing headline balance sheet metrics.

Non‑Underlying and Transformation Costs

Non‑underlying expenses after tax totaled $2.8 million, down from $4.8 million a year earlier but still notable. These costs related mainly to transformation and IT implementation projects, signaling that IPH is still mid‑cycle on its modernization drive even as one‑off charges taper.

Risk from Self‑Filed and AI‑Generated Applications

Management flagged the rapid growth of self‑filed and AI‑generated provisional applications in Australia as a structural threat to low‑margin filing work. While they argue IPH’s focus on secondary‑market mandates limits immediate revenue risk, the trend could reshape fee pools and competitive dynamics over time.

Timing and Exposure Risks in ANZ and U.S. Filings

IPH remains significantly exposed to U.S.‑origin filings, which are estimated to account for roughly 30% to 35% of its Australian patent work. Recovery prospects hinge on U.S. PCT trends and the success of efforts to diversify into Western Europe, Japan, South Korea and China, outcomes that remain uncertain.

Forward‑Looking Guidance and Strategic Focus

Looking ahead to FY 2026, management plans to leverage Canada’s integrated platform to capture benefits when the CIPO backlog finally unwinds and to build on Asia’s renewed growth and recent case transfers. At the same time, they aim to retarget ANZ business development away from U.S. PCT dependence, deepen AI‑driven efficiencies, sustain strong cash conversion and deploy capital through dividends, buybacks and a disciplined balance sheet.

IPH’s earnings call painted a picture of a global IP group in transition, with Canada and Asia gaining momentum as ANZ and Singapore lag. For investors, the combination of strong cash flow, rising dividends, lower leverage and a pipeline of potential backlog‑driven revenue offers upside, but execution on diversification and technology‑led efficiency will be crucial to unlock that potential.